Tesis Labs, a leader in targeted genetic sequencing, and Personal Genome Diagnostics (PGDx), a leader in cancer genomics, announced a new collaboration to maximize the power of genetic sequencing and bioinformatics. Through this collaboration, the companies intend to combine resources and expertise to create new genomics solutions that could combat cancer and improve outcomes for patients and advance market access initiatives to accelerate adoption in the market.

The National Institute of Health estimates that by 2040, there will be 29.5 million new cancer cases and nearly 16.4 million deaths worldwide per year. This new strategic collaboration brings together highly specialised clinical laboratory and biotechnology teams, enabling their expertise, creativity, and passion for delivering the latest genetic and bioinformatic insights to advance cancer predisposition, profiling, and treatment.

“We are excited to partner with PGDx and leverage our aligned vision and collective expertise to enable new and creative clinical opportunities,” stated Ron King, Tesis Labs CEO. “Genetic sequencing and genetic biomarkers are revealing new opportunities for medicine. Our clinical expertise and approaches to unlocking the power of genetic sequencing are bringing new insights to cancer research, profiling and treatment.”

``Tesis Labs, is a company that shares our passion for expanding the reach of genetic sequencing through decentralized testing,” said Megan Bailey, Chief Executive Officer of PGDx. “We look forward to working with Tesis Labs to further progress advancements in genomic insights and patient-centred oncology care.”

Tesis uses a genetically integrated medical platform for targeted genetic sequencing and comprehensive genetic data collection to support many medical specialities. The company’s existing labs are in Denver, Lafayette, Colo., and Houston.

PGDx currently offers three pan-cancer NGS kitted solutions – elio tissue complete, an FDA cleared kit, elio plasma complete, a comprehensive liquid biopsy solution, and elio plasma resolve, which has received FDA breakthrough device designation – that provide researchers and clinicians with the ability to identify biomarkers and profile tumours through advanced genomic sequencing within their own hospital systems and laboratories